# Stastical report for TEENS feasibility trial

### Using simulated data

#### Olsen MH

#### 03 marts 2021

### Contents

Table 1 - Baseline characteristics			
Feasibility outcomes	3		
Exploratory clinical outcomes	4		
DSHI-Y (primary)	4		
Kidscreen-10 (secondary)	5		
DASS-21 (secondary)	5		
DERS-16 (further)	5		
Normality	6		

Table 1 - Baseline characteristics


	Overall	A	В	Missing
n	30	15	15	
age (mean (SD))	16.27 (0.87)	$16.60 \ (0.74)$	15.93 (0.88)	0.0
age (median [IQR])	16.00 [16.00, 17.00]	17.00 [16.00, 17.00]	16.00 [15.50, 16.50]	0.0
gender = $1 (\%)$	16 (53.3)	7 (46.7)	9 (60.0)	0.0

## Feasibility outcomes


#### A) Completion of follow-up



#### B) The fraction of eligible participants who consent to inclusion and randomization




#### C) Compliance



Outcome	Fraction	LCL	UCL
A	0.867	0.684	0.056
В	0.00.	0.034 $0.215$	0.000
C	0.000	0.448	00-

#### Exploratory clinical outcomes

#### **DSHI-Y** (primary)



```
## Linear mixed-effects model fit by REML
##
   Data: temp1
##
          AIC
                   BIC
                          logLik
     4990.787 5014.522 -2489.393
##
##
## Random effects:
##
   Formula: ~1 | pt_id
           (Intercept) Residual
##
              20.29976 146.649
## StdDev:
##
## Fixed effects: result ~ time + group + time:group
##
                   Value Std.Error DF
                                         t-value p-value
## (Intercept) 236.58095 20.526893 358 11.525415 0.0000
                 2.30147 2.806711 358
                                        0.819987
  groupB
                43.06300 29.029411
                                    28
                                       1.483427
                                                  0.1491
               -6.89084 3.969289 358 -1.736040
  time:groupB
##
   Correlation:
##
               (Intr) time
                             groupB
               -0.820
## time
               -0.707 0.580
## groupB
## time:groupB 0.580 -0.707 -0.820
## Standardized Within-Group Residuals:
##
         Min
                      Q1
                                Med
                                            QЗ
                                                      Max
## -1.7725867 -0.8418055 -0.1024694 0.9246213
                                               1.7255403
##
## Number of Observations: 390
## Number of Groups: 30
```

Kidscreen-10 (secondary)

DASS-21 (secondary)

DERS-16 (further)

# Normality

